S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)
S&P 500   4,613.09 (+0.19%)
DOW   36,355.85 (+0.30%)
QQQ   393.68 (+0.39%)
AAPL   192.01 (-1.89%)
MSFT   368.94 (-1.41%)
META   321.87 (-3.27%)
GOOGL   132.36 (-1.95%)
AMZN   144.41 (-2.04%)
TSLA   240.85 (-1.23%)
NVDA   462.93 (-2.55%)
NIO   7.44 (+0.81%)
BABA   71.26 (-1.22%)
AMD   134.03 (+3.96%)
T   16.56 (-2.13%)
F   11.08 (+0.64%)
MU   77.77 (+3.75%)
CGC   0.79 (-0.73%)
GE   120.33 (-0.22%)
DIS   92.52 (-0.32%)
AMC   6.78 (-2.16%)
PFE   28.51 (-0.94%)
PYPL   59.49 (+0.93%)
XOM   99.32 (-0.23%)

ADC Therapeutics (ADCT) Stock Price, News & Analysis

$1.00
-0.02 (-1.83%)
(As of 10:41 AM ET)
Compare
Today's Range
$1.00
$1.05
50-Day Range
$0.47
$1.13
52-Week Range
$0.36
$5.75
Volume
43,736 shs
Average Volume
474,327 shs
Market Capitalization
$76.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.67

ADC Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
259.5% Upside
$3.67 Price Target
Short Interest
Bearish
6.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.38) to ($1.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

602nd out of 942 stocks

Biotechnology Industry

22nd out of 41 stocks


ADCT stock logo

About ADC Therapeutics Stock (NYSE:ADCT)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

ADCT Stock Price History

ADCT Stock News Headlines

ADC Therapeutics: Navigating A Swirling Drain
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Analyst Expectations for ADC Therapeutics's Future
Sobi to present new data at ASH 2023 Annual Meeting
TD Cowen Downgrades Adc Therapeutics (ADCT)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Q3 2023 ADC Therapeutics SA Earnings Call
What Wall Street expects from ADC Therapeutics's earnings
ADC Therapeutics SA ADCT
Puma Biotech (PBYI) Tops Q3 Earnings Estimates
See More Headlines
Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
317
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.67
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+259.5%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-155,800,000.00
Net Margins
-145.64%
Pretax Margin
-148.08%

Debt

Sales & Book Value

Annual Sales
$122.57 million
Book Value
$1.16 per share

Miscellaneous

Free Float
49,619,000
Market Cap
$78.35 million
Optionable
Not Optionable
Beta
1.24
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 50)
    M.S., CEO & Director
    Comp: $828.34k
  • Mr. Jose I. Carmona M.B.A. (Age 51)
    Chief Financial Officer
  • Dr. Patrick van Berkel Ph.D. (Age 55)
    Chief Scientific Officer
  • Dr. Michael Mulkerrin Ph.D. (Age 68)
    Chief Technical Operations Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Ms. Susan Romanus (Age 58)
    Chief Compliance & Quality Officer
  • Mr. Peter J. Graham Esq. (Age 56)
    Chief Legal Officer
  • Ms. Kimberly Pope (Age 56)
    Senior VP & Chief People Officer
  • Ms. Kristen Harrington-Smith (Age 50)
    Chief Commercial Officer
  • Dr. Mohamed Zaki M.D. (Age 58)
    Ph.D., Chief Medical Officer














ADCT Stock Analysis - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ADCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADCT, but not buy additional shares or sell existing shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 1-year price objectives for ADC Therapeutics' shares. Their ADCT share price targets range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $3.67 in the next year. This suggests a possible upside of 259.5% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2023?

ADC Therapeutics' stock was trading at $3.84 on January 1st, 2023. Since then, ADCT shares have decreased by 73.4% and is now trading at $1.02.
View the best growth stocks for 2023 here
.

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 3,620,000 shares, a drop of 8.8% from the October 31st total of 3,970,000 shares. Based on an average trading volume of 297,800 shares, the days-to-cover ratio is currently 12.2 days. Currently, 6.8% of the company's stock are sold short.
View ADC Therapeutics' Short Interest
.

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our ADCT earnings forecast
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its earnings results on Tuesday, November, 7th. The company reported ($0.58) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.03. The company had revenue of $14.49 million for the quarter, compared to the consensus estimate of $14.57 million. ADC Therapeutics had a negative net margin of 145.64% and a negative trailing twelve-month return on equity of 1,121.94%.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), RTX (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an IPO on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Redmile Group LLC (18.46%), Affinity Asset Advisors LLC (1.43%), Acadian Asset Management LLC (0.20%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:ADCT) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -